STOCK TITAN

Sana Biotechnology Inc - SANA STOCK NEWS

Welcome to our dedicated news page for Sana Biotechnology (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sana Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sana Biotechnology's position in the market.

Rhea-AI Summary
Sana Biotechnology, Inc. achieves lasting glucose control in non-human primates with HIP-modified pancreatic islet cells, enabling insulin independence without immunosuppression. Anti-CD47 antibody demonstrates graft ablation safety strategy. The company aims to revolutionize type 1 diabetes treatment with potential clinical trials on the horizon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.15%
Tags
none
-
Rhea-AI Summary
Sana Biotechnology, Inc. successfully closed an underwritten upsized public offering, raising approximately $189.75 million by selling 21,772,728 shares of common stock and pre-funded warrants. The offering included the full exercise of the underwriters' option to purchase additional shares, with major investment banks acting as joint book-running managers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
offering
-
Rhea-AI Summary
Sana Biotechnology, Inc. (Nasdaq: SANA) has announced the pricing of its upsized public offering of 17,272,728 shares of common stock at $5.50 per share and pre-funded warrants to purchase 12,727,272 shares at $5.4999 per pre-funded warrant. The company has also granted the underwriters a 30-day option to purchase up to an additional 4,500,000 shares of its common stock. The gross proceeds from the offering are expected to be approximately $165.0 million before deducting underwriting discounts and commissions and other offering expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
offering
Rhea-AI Summary
Sana Biotechnology, Inc. has announced an underwritten public offering of $125.0 million of shares of its common stock, with the intention to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering. Morgan Stanley, J.P. Morgan, Goldman Sachs & Co. LLC, and BofA Securities are acting as joint book-running managers for the proposed offering. The proposed offering is being made pursuant to a Registration Statement on Form S-3, including a base prospectus, previously filed with and declared effective by the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
offering
-
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) has received FDA clearance to initiate a study of SC262 in patients with relapsed or refractory B-cell malignancies, particularly those who have received prior CD19-directed CAR T therapy. The company aims to address the significant unmet need for patients who have failed CD19-directed CAR T therapy by introducing SC262, which has shown durable complete responses in a substantial number of patients in the relapse setting. Sana has received three IND regulatory clearances and supported the authorization of an investigator-sponsored CTA to begin new studies utilizing their hypoimmune platform in seven different indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes. The company is expected to disclose initial proof of concept data for SC262 in 2024, presenting data from all of their studies this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
clinical trial
-
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024. The presentation will include a business overview and update by Steve Harr, Sana’s President and CEO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
conferences
Rhea-AI Summary
Sana Biotechnology, a company listed as NASDAQ: SANA, announced preclinical data supporting the anti-tumor and immune evasion capabilities of allogeneic CAR T cells engineered with Sana’s proprietary hypoimmune (HIP) technology at the 65th American Society of Hematology (ASH) Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
clinical trial
-
Rhea-AI Summary
Sana Biotechnology, a company focused on engineered cells, announced the publication in Blood of initial clinical data from the ARDENT Phase 1 clinical trial with SC291, a hypoimmune (HIP)-modified allogeneic CD19-directed CAR T cell therapy. SC291 appeared safe and well tolerated, evaded immune detection, and induced a partial response in a patient with chronic lymphocytic leukemia (CLL). ARDENT is a Phase 1 study evaluating safety and tolerability of SC291 in patients with CLL and non-Hodgkin lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
Sana Biotechnology, Inc. (SANA) will present at two investor conferences in November and December, featuring a business overview and update. The company will present at the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023, and at the JMP Securities Hematology and Oncology Summit on December 6, 2023. Webcasts will be accessible on Sana's Investor Relations page with replays available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
conferences
Rhea-AI Summary
Sana Biotechnology, Inc. (NASDAQ: SANA) and Uppsala University Hospital in Sweden have announced the authorization of Uppsala University’s Clinical Trial Application (CTA) to initiate a first-in-human study of UP421, an allogeneic, primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, in patients with type 1 diabetes. The goal is to provide proof of concept for transplanting functional islet cells without immunosuppression. The study will focus on safety, cell survival, immune evasion, and C-peptide production. Insights from this study may inform the development of Sana’s SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
clinical trial
Sana Biotechnology Inc

Nasdaq:SANA

SANA Rankings

SANA Stock Data

2.18B
113.75M
9.32%
80.88%
10.87%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Seattle

About SANA

sana biotechnology is focused on utilizing engineered cells as medicines for patients. the ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. sana is building differentiated capabilities across the spectrum of cell and gene therapy. three aspirations drive sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. the first is the ability to repair and control the genes in any cell in the body. we are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. last is a belief we can enable broader access to ou